QSAM Biosciences, Inc. (QSAM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QSAM Biosciences, Inc. (QSAM) trades at $8.30. QSAM Biosciences, Inc. is a biotechnology company focused on developing nuclear medicines for cancer treatment. Their lead candidate, CycloSam, targets bone cancer using a radioisotope, Samarium-153 DOTMP. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for QSAM: QSAM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QSAM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on QSAM.
How is this calculated? →QSAM Biosciences, Inc. (QSAM) Healthcare & Pipeline Overview
QSAM Biosciences, Inc. is a clinical-stage biotechnology firm specializing in radiopharmaceuticals for oncology, particularly bone cancer. Their lead drug, CycloSam, leverages targeted radioisotope therapy, positioning them in the niche market of nuclear medicine with potential for addressing unmet needs in cancer treatment.
What Is the Investment Thesis for QSAM?
QSAM Biosciences, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The investment thesis hinges on the successful development and commercialization of CycloSam. Key value drivers include positive clinical trial results demonstrating efficacy and safety, regulatory approval from the FDA, and successful market penetration. The company's small size and limited resources pose significant risks, including potential delays in clinical development, challenges in securing funding, and competition from larger pharmaceutical companies. The current market capitalization of $0.00B reflects the early stage of the company and the inherent uncertainties in drug development. Investors should closely monitor clinical trial progress and regulatory milestones.
Based on FMP financials and quantitative analysis
QSAM Key Highlights
QSAM Biosciences is focused on developing CycloSam, a clinical-stage bone-targeting radiopharmaceutical.
- The company operates in the nuclear medicine space, a specialized area within oncology.
- QSAM Biosciences has a license agreement with IGL Pharma, Inc.
- The company changed its name from Q2Earth, Inc. in September 2020 to reflect its focus on biotechnology.
- The company's P/E ratio is -6.67, reflecting its current lack of profitability.
Who Are QSAM's Competitors?
QSAM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CTBO Cantabio Pharmaceuticals, Inc. | $1.01 | +0.00% | 50 | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QSAM's Key Strengths?
Focus on a specific niche within oncology (bone-targeting radiopharmaceuticals).
- Clinical-stage asset (CycloSam) with potential for significant impact.
- License agreement with IGL Pharma, Inc.
- Experienced management team in radiopharmaceuticals.
What Are QSAM's Weaknesses?
Limited financial resources and small team size.
- Dependence on the success of a single drug candidate (CycloSam).
- High regulatory hurdles and clinical trial risks.
- Lack of established commercial infrastructure.
What Could Drive QSAM Stock Higher?
Announcement of clinical trial results for CycloSam.
- Potential FDA approval of CycloSam for bone cancer treatment.
- Pursuit of strategic partnerships with larger pharmaceutical companies.
- Efforts to secure funding and maintain operations.
What Are the Key Risks for QSAM?
Financial-distress signal — its Altman Z-Score of -39.48 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for CycloSam.
- Regulatory setbacks or rejection of CycloSam.
- Competition from established pharmaceutical companies.
- Limited financial resources and potential for dilution.
- Dependence on the success of a single drug candidate.
What Are the Growth Opportunities for QSAM?
- Advancement of CycloSam through Clinical Trials: The primary growth opportunity lies in successfully completing clinical trials for CycloSam and demonstrating its efficacy in treating bone cancer. Positive clinical trial results would significantly increase the company's valuation and attract potential partners or acquirers. The timeline for this growth driver depends on the pace of clinical trial enrollment and data analysis, with potential milestones expected over the next 2-3 years. The market size for bone cancer therapeutics is estimated to be in the billions of dollars.
- Expansion of CycloSam to Other Cancer Types: QSAM could explore the potential of CycloSam to target other types of cancer beyond bone cancer. This would require additional research and development efforts, but could significantly expand the market opportunity for the drug. The timeline for this growth driver is longer-term, potentially 3-5 years, and depends on the success of initial clinical trials and preclinical studies. The market size for broader cancer therapeutics is substantial, reaching hundreds of billions of dollars.
- Strategic Partnerships and Collaborations: QSAM can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of CycloSam. These partnerships could provide access to funding, expertise, and infrastructure, which would be crucial for the company's growth. The timeline for this growth driver is ongoing, as the company actively seeks potential partners. The impact of partnerships on market size and revenue is dependent on the specific terms of the agreements.
- Orphan Drug Designation and Regulatory Exclusivity: Obtaining orphan drug designation for CycloSam could provide QSAM with regulatory exclusivity and other benefits, such as tax credits and reduced regulatory fees. This would enhance the drug's market potential and provide a competitive advantage. The timeline for this growth driver is dependent on the regulatory approval process, with potential milestones expected within the next 1-2 years. The financial benefits of orphan drug designation can be significant, potentially adding millions of dollars in value.
- Development of New Radiopharmaceuticals: QSAM can leverage its expertise in nuclear medicine to develop new radiopharmaceuticals for the treatment of other diseases. This would diversify the company's product pipeline and reduce its reliance on CycloSam. The timeline for this growth driver is longer-term, potentially 5+ years, and depends on the success of research and development efforts. The market size for new radiopharmaceuticals is dependent on the specific diseases targeted.
What Are QSAM's Competitive Advantages?
- Proprietary radiopharmaceutical technology.
- Patent protection for CycloSam.
- Expertise in nuclear medicine and targeted therapies.
- Potential for orphan drug designation.
What Does QSAM Do?
QSAM Biosciences, Inc., originally incorporated in 2004 as Q2Earth, Inc., rebranded in September 2020 to reflect its focus on nuclear medicine. Headquartered in Austin, Texas, the company is dedicated to developing radiopharmaceuticals for the treatment of cancer and related diseases. Their primary focus is CycloSam (Samarium-153 DOTMP), a clinical-stage bone-targeting radiopharmaceutical. CycloSam is designed to deliver targeted radiation therapy to bone tumors, potentially offering a more effective and less toxic treatment option compared to traditional chemotherapy or external beam radiation. The company operates with a small team, emphasizing strategic partnerships and collaborations to advance its clinical programs. QSAM has a license agreement with IGL Pharma, Inc., which likely supports aspects of their research and development efforts. As a biotechnology company, QSAM's success hinges on the clinical trial outcomes and regulatory approvals for CycloSam.
What Products and Services Does QSAM Offer?
- Develops nuclear medicines for cancer treatment.
- Focuses on targeted radiopharmaceutical therapies.
- Conducts clinical trials for its lead drug candidate, CycloSam.
- Seeks regulatory approval for its products.
- Engages in research and development of new cancer treatments.
- Collaborates with other companies and research institutions.
How Does QSAM Make Money?
- Develops and patents radiopharmaceutical drugs.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Potentially commercializes drugs directly or through partnerships.
What Industry Does QSAM Operate In?
QSAM Biosciences operates within the biotechnology and nuclear medicine sectors, both characterized by high growth potential and significant regulatory hurdles. The market for cancer therapeutics is substantial, driven by an aging population and increasing cancer incidence rates. The competitive landscape includes established pharmaceutical companies and specialized biotechnology firms developing novel cancer treatments. QSAM's focus on radiopharmaceuticals positions it in a niche market with potential for targeted therapies, but also requires specialized expertise and infrastructure. The biotechnology industry is subject to intense competition, rapid technological advancements, and evolving regulatory requirements.
Who Are QSAM's Key Customers?
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Patients with bone cancer and other cancers.
Company Profile
QSAM Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Douglas R. Baum. QSAM has traded publicly since 2012.
Key Financial Metrics
A current ratio of 1.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
QSAM Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.48 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 12 insider filings for QSAM Biosciences, Inc. break down as 10 sales and 2 purchases. On net that is roughly 41K shares disposed (about $238K), a signal worth weighing alongside the fundamentals.
QSAM Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in QSAM's future prospects, indicating that insiders believe the company is undervalued.
- Community sentiment has shifted positively, with discussions highlighting the potential of QSAM's innovative therapies.
- Recent announcements regarding advancements in clinical trials have generated excitement among investors and analysts alike.
- The growing interest in biotech stocks, especially those focusing on unique treatment solutions, positions QSAM favorably in the current market.
Bear Case
- Concerns linger about the overall volatility in the biotech sector, which may impact QSAM's stock performance.
- Some community members express skepticism about the company's ability to deliver on its clinical trial promises, leading to cautious sentiment.
- Insider selling activity in the past raises questions about the long-term commitment of key stakeholders to the company's vision.
- Market perception remains cautious due to broader economic uncertainties, which could affect investment in speculative biotech companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QSAM Latest News
No recent news available for QSAM.
QSAM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QSAM.
Price Targets
Wall Street price target analysis for QSAM.
QSAM MoonshotScore
What does this score mean?
The MoonshotScore rates QSAM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Douglas R. Baum
CEO
Douglas R. Baum serves as the CEO of QSAM Biosciences, Inc. His background includes experience in managing and leading small teams, as evidenced by his current role overseeing the company's four employees. Further details regarding his specific career history, educational background, and previous roles are not available in the provided data. However, his leadership is crucial for guiding QSAM through its clinical development and regulatory milestones.
Track Record: Due to the limited information available, it is difficult to assess Douglas R. Baum's specific track record at QSAM Biosciences. However, as CEO, he is responsible for overseeing the development of CycloSam and securing funding for the company's operations. The success of QSAM will depend on his ability to navigate the challenges of drug development and regulatory approval.
QSAM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that QSAM Biosciences may not meet the minimum financial or disclosure requirements of the higher OTC tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial resources and potential for dilution.
- Lack of regulatory oversight and transparency.
- Thin trading volume and price volatility.
- Potential for fraud or manipulation.
- Dependence on the success of a single drug candidate.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's intellectual property and patent protection.
- Evaluate the clinical trial data for CycloSam.
- Understand the regulatory pathway for CycloSam.
- Assess the company's funding needs and potential for dilution.
- Consult with a financial advisor before investing.
- Focus on developing nuclear medicines for cancer treatment.
- Clinical-stage asset (CycloSam) with potential for significant impact.
- License agreement with IGL Pharma, Inc.
- Experienced management team in radiopharmaceuticals.
QSAM Healthcare Stock FAQ
What does QSAM Biosciences, Inc. do?
QSAM Biosciences, Inc. is a biotechnology company focused on the development of nuclear medicines for the treatment of cancer, particularly bone cancer. Their lead product candidate, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical designed to deliver targeted radiation therapy to bone tumors.
What do analysts say about QSAM stock?
As of March 18, 2026, formal analyst coverage of QSAM Biosciences, Inc. is limited due to its early stage and OTC market listing. Key valuation metrics such as revenue projections and earnings estimates are not widely available. The company's growth prospects are primarily tied to the successful development and commercialization of CycloSam.
What are the main risks for QSAM?
The main risks for QSAM Biosciences, Inc. include the inherent uncertainties in drug development, such as clinical trial failures or delays, regulatory setbacks, and competition from established pharmaceutical companies. The company's limited financial resources and dependence on the success of a single drug candidate (CycloSam) also pose significant risks.
What are the key factors to evaluate for QSAM?
Evaluate QSAM on fundamentals, analyst consensus, and risk factors. QSAM Biosciences, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. Not financial advice.
How frequently does QSAM data refresh on this page?
QSAM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QSAM's recent stock price performance?
QSAM Biosciences, Inc. (QSAM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific niche within oncology (bone-targeting radiopharmaceuticals). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QSAM overvalued or undervalued right now?
QSAM Biosciences, Inc. (QSAM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QSAM before investing?
Before investing in QSAM Biosciences, Inc. (QSAM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.